Quick Facts: Megestron

• Treats advanced breast cancer and advanced endometrial cancer.
• Manages unexplained, significant weight loss, anorexia, or cachexia in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS).

Megestron, known by its active substance megestrol acetate, is prescribed to address specific health conditions. The primary therapeutic uses fall into two distinct areas.

First, Megestron is indicated for the palliative treatment of advanced forms of hormone-dependent cancer, specifically advanced breast cancer and advanced endometrial cancer (cancer of the uterus lining). It works by influencing the hormone balance in the body, which can interfere with the proliferation of cancer cells.

Second, the oral suspension form of Megestron is used for the management of severe, unexplained significant weight loss that presents as anorexia or cachexia (wasting syndrome) in patients with a diagnosis of AIDS. This therapeutic action is associated with an enhancement of appetite, which can result in weight gain. It is not intended for use as a preventative measure for weight loss, and other treatable causes of weight loss must be addressed before therapy is initiated.

Who Can and Cannot Use Megestron?

This section defines the officially documented population eligibility and non-eligibility for Megestrol Acetate based on regulatory labeling.

Populations for Whom Use is Contraindicated

Eligibility Across Age Groups and Physiological States

Megestron is officially intended for adult patients in its labeled uses. Safety and effectiveness have not been established in pediatric patients [Source 1.7]. For older adults (geriatric patients), use requires caution and monitoring due to the potential for decreased renal or hepatic function [Source 1.2].

Nursing mothers are advised that nursing should be discontinued during treatment [Source 1.8].

Conditions Requiring Restricted Use

Use of Megestron requires caution and monitoring in patients with a history of thromboembolic disease (e.g., blood clots) or diabetes mellitus [Source 1.2]. Caution is also advised for patients with impaired renal or hepatic function [Source 1.9]. Women of childbearing potential are required to use effective contraception during therapy [Source 1.8].

Megestron Interactions with other medicines and products

Official regulatory documents define the product's interaction profile across three main domains: pharmacokinetic changes, pharmacodynamic effects, and population-specific considerations.

Documented Interaction Patterns

Official Restrictions and Constraints

There are no drug-drug combinations formally listed as contraindications in the regulatory labeling's core safety sections, and no mandated dose timing separation rules are documented.

However, the official labeling includes caution for Geriatric Patients due to the higher likelihood of decreased hepatic, renal, or cardiac function, which may increase the risk or severity of interactions. Regarding food and alcohol, regulatory information states there are no known interactions with foods or drinks, and it is unknown if drinking alcohol will affect Megestrol Acetate.

Megestron (megestrol acetate) functions primarily as a synthetic agonist of the nuclear progesterone receptor (PR). The ligand-receptor complex translocates to the nucleus and binds to specific DNA sequences, modulating the transcription of target genes. This action alters protein synthesis and cellular proliferation pathways in reproductive tissues.

Megestrol also exhibits a significant agonist interaction with the Glucocorticoid Receptor (GR). Activation of the GR leads to the transcriptional regulation of various metabolic genes, influencing catabolic and anabolic pathways. This includes potential systemic modulation of pro-inflammatory mediators, such as the suppression of Interleukin-6 (IL-6) and Tumor Necrosis Factor-alpha (TNF- alpha) levels, and the upregulation of orexigenic neuropeptides like Neuropeptide Y (NPY) in central nervous system regions. Additionally, as a progestin, it exerts an antigonadotropic effect by inhibiting Luteinizing Hormone (LH) release from the pituitary gland, which subsequently reduces ovarian estrogen secretion.

Official Administration Guidelines for Megestron

Megestron (megestrol acetate) is administered strictly through the oral route as either a tablet or a liquid suspension. The specific dosage and frequency are determined by the condition being treated.

Approved Dosing Regimens

Dosing recommendations may vary by region; the following regimens represent standard clinical applications for the medication.

For cancer indications, a minimum of two months of continuous treatment is generally recommended before evaluating efficacy.

Administration and Handling

When using the oral suspension, the container must be shaken well before each dose is measured. It is critical to note that the different concentrations of the liquid formulation, such as 40 mg/mL and 125 mg/mL, are not mg/mg substitutable due to differing bioavailability.

Population-Specific Rules

Dose selection for older adults should be cautious, often starting at the lower end of the established range, due to the higher prevalence of decreased organ function. Use in pediatric patients is not generally recommended as safety and effectiveness have not been established for the approved indications.

Megestron: Recent Clinical Evidence

Recent clinical research has focused on the use of megestrol acetate (often referred to as Megestron in a general context) for treating anorexia/cachexia syndrome (significant, unintended weight loss) primarily in patients with cancer.

Controlled trials and meta-analyses consistently suggest that megestrol acetate, when compared to a placebo, is associated with both improved appetite and a greater probability of weight gain in patients experiencing this syndrome. In studies involving patients with cancer, relative risks for appetite improvement were observed to be notably higher in those receiving megestrol acetate compared to controls, alongside a moderate increase in the rate of weight gain.

Limitations and Specific Findings

While weight changes are frequently observed, research has generally not demonstrated a clear benefit on overall quality of life or survival measures in patients with cancer-related cachexia who receive megestrol acetate. The weight gained in clinical settings is often reported to be primarily adipose tissue (fat) rather than lean body mass (muscle).

Clinical trials have explored different formulations, with some investigational nanocrystalline suspensions suggesting potentially greater weight gain and appetite benefits compared to conventional tablet formulations, though more data is needed to confirm these findings.

Safety Considerations in Studies

In addition to the therapeutic findings, clinical evidence highlights important safety considerations. Participants receiving megestrol acetate were observed to have a higher risk of adverse events overall compared to those on placebo. Specific risks noted across multiple studies include an increased risk of venous thromboembolic events (VTE) (blood clots), especially when used concurrently with chemotherapy, and the potential for adrenal suppression.

Common questions about Megestron (FAQ)

Q: Does Megestron affect blood sugar levels for someone without pre-existing diabetes?

A: Regulatory documents indicate that megestrol acetate has been associated with changes in glucose (blood sugar) control. Postmarketing reports include cases of new onset diabetes mellitus and glucose intolerance, meaning there is a potential for blood sugar to be affected even in patients who did not have diabetes beforehand. This information is noted alongside the potential for exacerbating pre-existing diabetes.

Q: Is it safe to drink alcohol while taking Megestron?

A: The official product labeling for megestrol acetate does not include a direct, explicit warning against combining the medication with alcohol. However, the liquid form of the medicine (the oral suspension) may contain a minimal amount of alcohol derived from the flavoring used in the formula. Patients are generally advised to review the latest official product information for guidance on alcohol and medication use.

Q: How long does it typically take to see an improvement in appetite after starting Megestron?

A: Clinical trial data that studied the effect of megestrol acetate on appetite focused on a 12-week evaluation period. In these studies, patients receiving the medication reported improvements in appetite. While this timeframe was used for study evaluation, the onset of individual response can vary among patients.

Q: If I'm taking the oral suspension, what is the best way to measure a dose accurately?

A: The official prescribing information for the oral suspension emphasizes the importance of accuracy by instructing patients to shake the container well before use. Since the dose is measured in precise units (e.g., milliliters), accurate measurement requires the use of a calibrated measuring device to help ensure the correct volume is administered.

Megestron (megestrol acetate) should be stored in a tightly closed container at room temperature, typically between 68 mathrmF and 77 mathrmF (20 mathrmC and 25 mathrmC), away from excessive heat, moisture, and direct light. Do not store this medication in the bathroom.

Keep all forms of megestrol out of sight and reach of children and pets.

Proper disposal is essential for safety and environmental protection. Do not flush unused or expired medication down the toilet or pour it down a drain unless specifically instructed to do so. It is generally recommended to utilize local drug take-back programs at pharmacies or police stations. If a take-back program is unavailable, mix the medication with an unappealing substance like dirt, cat litter, or used coffee grounds, place the mixture in a sealed bag or container, and discard it in your household trash. Scratch out all personal information on the prescription label before discarding the original packaging.